Infectious Disease Therapeutics Market Size | Share and Trends 2024 to 2034

The global infectious disease therapeutics market size was USD 119.37 billion in 2023, calculated at USD 123.91 billion in 2024 and is expected to reach around USD 179.91 billion by 2034, expanding at a CAGR of 3.8% from 2024 to 2034.

  • Last Updated : August 2024
  • Report Code : 2056
  • Category : Healthcare

Infectious Disease Therapeutics Market Size and Growth 2024 to 2034

The global infectious disease therapeutics market size accounted for USD 123.91 billion in 2024 and is expected to reach around USD 179.91 billion by 2034, expanding at a CAGR of 3.8% from 2024 to 2034. The North America infectious disease therapeutics market size reached USD 47.75 billion in 2023.

Infectious Disease Therapeutics Market Size 2024 to 2034

Infectious Disease Therapeutics Market Key Takeaways

  • North America led the global market with the highest market share of 40% in 2023.
  • By mode of treatment, the drugs segment has held the largest market share in 2023.
  • By target organism, the antibacterial segment captured the biggest revenue share in 2023.
  • By infection type, the bacterial infection segment registered the maximum market share in 2023.
  • By distribution channel, the hospital segment is estimated to hold the highest market share in 2023.

U.S. Infectious Disease Therapeutics Market Size and Growth 2024 to 2034

The U.S. infectious disease therapeutics market size was estimated at USD 33.49 billion in 2023 and is predicted to be worth around USD 51.55 billion by 2034, at a CAGR of 4% from 2024 to 2034.

U.S. Infectious Disease Therapeutics Market Size 2024 to 2034

On the basis of geography, the region of North America has emerged as the largest market for infectious disease therapeutics pertaining to the increasing prevalence of infectious diseases in this region. North America accounted highest revenue share 40% in 2023. The huge number of people belonging to the geriatric population in this region has become a major growth factor for the infectious disease therapeutics market. Higher disposable income available with the people has also emerged as a major growth factor for the market. Advanced health care facilities provided by the government in the form of reimbursement policies has supported the growth of the market to a great extent.

Infectious Disease Therapeutics Market Share, By Region, 2023 (%)

The next region which has shown a tremendous growth is that of Asia Pacific which accounts for a considerable share in the global market for infectious disease therapeutics. The European region has also shown a considerable growth over the period of years.

Market Overview

Infectious diseases spread from one person to another by indirect or direct contact. For treating infectious diseases medicines which are anti-infective in nature need to be consumed by the patients. These diseases are mainly caused due to pathogens like viruses, bacteria, fungi and parasites. The defense system of the host is acted upon directly with a view to target the organism that is causing the disease and cure is brought into effect. The huge number of people belonging to the geriatric population has emerged as a great opportunity for the growth of the infectious disease therapeutics market.

The outbreak of the and make was an example of an infectious disease which was caused due to coronavirus. The occurrence of this pandemic emerged as a major growth factor for the infectious disease therapeutics market. The huge number of technologically advanced medicines that were launched during the course of the pandemic has helped the market to record a tremendous revenue over the period of time.

Growth Factors

The increasing prevalence of infectious diseases in the society has emerged as a major growth factor for the therapeutic system as well. Advanced medicines have been launched by the key market players for treating infectious diseases with a view to produce better profits. Initiatives have been taken by the government for providing advanced facilities to the citizens in order to treat infectious diseases.

A huge number of people who belong to the genetic population has emerged as a major opportunity for the growth of the market. A rise in the disposable income available with the people has emerged as a major opportunity as well. A high disposable income enables the people to opt for advanced treatment options which helps the growth of the market.

Insurance companies are providing attractive reimbursement policies that are supporting the expenses of the people and hence they are opting for better treatment options to get themselves treated in a shorter period of time. The extensive research and development programs carried out by the key market players with a view to introduce modern medicines into the society has help the market to record a considerable revenue over the period of time.

  • Increasing number of cases suffering with infectious diseases
  • Government initiatives to enhance health care system
  • Attractive reimbursement policies
  • Huge number of people belonging to geriatric population
  • Increasing disposable income available with the people
  • Modern medicines introduced by key market players

Market Scope

Report Coverage Details
Market Size in 2023 USD 119.37 Billion
Market Size in 2024 USD 123.91 Billion
Market Size by 2034 USD 179.91 Billion
Growth Rate from 2024 to 2034 CAGR of 3.8%
Base Year 2023
Forecast Period 2024 to 2034
Segments Covered Mode of Treatment, Target Organism, Infection Type, Distribution Channel and Region
Regions Covered North America, Asia Pacific, Europe, Latin America, Middle East and Africa

 

Market Dynamics

Key Market Drivers

  • Increasing prevalence of diseases among the people- the number of people who are suffering with infectious disease has increased tremendously over the period of time what is resulting from the low immunity system possessed by them which is the after effect of the faulty food habits and sedentary lifestyle practiced by them. An improper lifestyle hampers the immunity power of the person and hence they tend to acquire infectious diseases more commonly as compared to the earlier period.
  • Increasing prevalence of antiviral drugs- The increasing consumption of antiviral drugs by the people which is dispensed over the counter shows an immediate effect on the body of the individual but hampers the immunity system to a great extent as it does not let the body to fight against the disease pathogens on its own which makes the system of the body weak and fragile.
  • Government initiatives- the active steps taken by the government to support the health care system by providing modern facilities to the people has boosted the market for infectious disease therapeutics to a great extent by attracting the potential consumers over the period of time.

Key Market Challenges

  • High cost of treatment- the high cost associated with the treatment of infectious diseases with technologically advanced medicines challenges the growth of the market to a great extent as it imposes an additional pressure on the disposable income of the people. The increasing demanding supply of generic drugs in the market has also challenged the growth of the branded drugs which treat infectious diseases.
  • Lack of skilled professionals- a major challenge which is faced by the infectious disease therapeutics market is the shortage of skilled professionals in the sector which hampers the growth of the market to a great extent. 

Key Market Opportunities

  • Increasing acceptance to advanced mode of treatments- people all over the world are accepting the use of modern medicines which are technologically advanced which is helping the infectious disease therapeutics market to show a tremendous growth over the over the period of time and provides a great opportunity to the growth of the market.
  • Disposable income- the presence of higher disposable income available with the people enables them to purchase the technically advanced medicines which show a faster effect on the body and helps to restore health in a shorter period of time. This emerges as a major opportunity for the growth of the market.
  • Attractive reimbursement policies- various initiatives taken by the government to support the healthcare system by providing attractive reimbursement policies to the people through insurance companies has encouraged people to opt for technically advanced treatment options which has emerged as a major opportunity for the growth of the market.

Mode of Treatment Insights

On the basis of the mode of treatment, the segment of drugs has emerged as the fastest-growing market owing to its largest share in the global economy. Increasing demand for advanced drugs in the market has helped in this segment to record a considerable revenue over the period of time and it's foreseen to continue its growth in a similar fashion during the future as well. The huge number of people belonging to the geriatric population has emerged as a major opportunity for the segment of drugs as it is the most common line of treatment opted by these people. The availability of medicines over the counter has also proved to be a major opportunity for the growth of the drug segment. Increasing disposable income available with the people has enabled them to opt for advanced drugs available in the market for the purpose of treatment. The other segment which has been discussed under this category includes vaccines which has become a common entity after the birth of a child to the period up till when new diseases keep on emerging into the market along with their vaccinations.

Target Organism Insights

On the basis of the target organism, the segment of antibacterial has emerged as the largest market due to its significant share in the global economy. The contribution of the anti-bacterial segment is expected to grow further at a faster rate during the future as well. The increasing prevalence of diseases which spread through the mode of bacteria has boosted the market for the antibacterial segment to a great extent. Increasing prevalence of diseases such as hepatitis A, influenza, tuberculosis, HIV and hepatitis C Merged as a major opportunity for the growth of the anti-bacterial segment in the current market. Increasing disposable income available with the people has emerged as a major opportunity for the sales and demand of advanced antibacterial drugs in the market.

Infection Type Insights

On the basis of infection type, the segment of bacterial infection has emerged as the fastest growing market over the period of time and is expected to show a tremendous boost during the future period as well. The increasing research and development programs conducted by the key market players with a view to introduce innovative medicines that are technologically advanced has helped the segment of bacterial infection to record a considerable growth over the period of time. The huge number of people who suffer with bacterial infection has also emerged as a major opportunity for the growth of the market. The weekend immunity system of the people provides a great opportunity for the bacteria to spread the infectious diseases and hence a considerable growth is recorded over the period of time.

Distribution Channel Insights

On the basis of distribution channel, the segment of hospitals has emerged as the fastest growing market as it proves to be the primary center where a patient shows up first when they are infected buy an infection and hence this sector has recorded a considerable revenue over the period of time. The huge number of people visiting the hospital sector on a daily basis for treating infectious diseases has also proved to be a major growth factor for the market. Dream basement policies and other facilities provided by the hospital sector through the insurance companies emerges as an attractive opportunity for the growth of the market. A number of different facilities are available in the hospital sector which prevents the patient from running to different centers which emerges as another opportunity for the growth of the market.

Infectious Disease Therapeutics Market Companies

  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc. (U.K)
  • Merck & Co. (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • AstraZeneca (U.K)
  • Mylan N.V. (U.S.)
  • Novartis AG (Switzerland)
  • Sanofi (France)

Recent Developments

  • In March 2021 - with a view to understand the mutations of the coronavirus in detail Cobas SARS-CoV-2 Variant Set 1 assay was introduced by Roche Diagnostics.

Segments covered in the report

By Mode of Treatment

  • Vaccines
  • Drugs

By Target Organism

  • Antifungal
  • Antiviral
  • Antibacterial
  • Anti-parasite
  • Others

By Infection Type

  • Viral
  • Parasitic 
  • Fungal
  • Bacterial
  • Others

By Distribution Channel

  • Clinic
  • Hospitals
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global infectious disease therapeutics market size was accounted at USD 119.37 billion in 2023 and it is expected to reach around USD 179.91 billion by 2034.

The global infectious disease therapeutics market is poised to grow at a CAGR of 3.8% from 2024 to 2034.

The major players operating in the infectious disease therapeutics market are Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K), Merck & Co. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca (U.K), Mylan N.V. (U.S.), Novartis AG (Switzerland)and Sanofi (France)

The increasing prevalence of infectious diseases all over the world has emerged as a major driving force for the growth of the market.

North America region will lead the global infectious disease therapeutics market during the forecast period 2024 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Meet the Team

Deepa Pandey, one of our esteemed authors, plays a crucial role in shaping the high-quality content that defines our research reports. Deepa holds a Master's in Pharmacy with a specialization in Pharmaceutical Quality Assurance, equipping her with an in-depth understanding of the healthcare industry's regulatory, quality, and operational nuances. With 2+ years of experience in market research, Deepa has made

Learn more about Deepa Pandey

With over 14 years of experience, Aditi is the powerhouse responsible for reviewing every piece of data and content that passes through our research pipeline. She is not just an expert—she’s the linchpin that ensures the accuracy, relevance, and clarity of the insights we deliver. Aditi’s broad expertise spans multiple sectors, with a keen focus on ICT, automotive, and various other cross-domain industries.

Learn more about Aditi Shivarkar

Related Reports